These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 18488877

  • 1. Raloxifene for older women: a review of the literature.
    Hansdóttir H.
    Clin Interv Aging; 2008; 3(1):45-50. PubMed ID: 18488877
    [Abstract] [Full Text] [Related]

  • 2. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
    Cranney A, Adachi JD.
    Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
    [Abstract] [Full Text] [Related]

  • 3. Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.
    Ko SS, Jordan VC.
    Expert Opin Pharmacother; 2011 Mar; 12(4):657-74. PubMed ID: 21294695
    [Abstract] [Full Text] [Related]

  • 4. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D, Spencer CM.
    Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Recommendations for raloxifene use in daily clinical practice in the Swiss setting.
    Lippuner K, Buchard PA, De Geyter C, Imthurn B, Lamy O, Litschgi M, Luzuy F, Schiessl K, Stute P, Birkhäuser M.
    Eur Spine J; 2012 Dec; 21(12):2407-17. PubMed ID: 22739699
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.
    Lippman ME, Krueger KA, Eckert S, Sashegyi A, Walls EL, Jamal S, Cauley JA, Cummings SR.
    J Clin Oncol; 2001 Jun 15; 19(12):3111-6. PubMed ID: 11408508
    [Abstract] [Full Text] [Related]

  • 14. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.
    Muchmore DB.
    Oncologist; 2000 Jun 15; 5(5):388-92. PubMed ID: 11040275
    [Abstract] [Full Text] [Related]

  • 15. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
    Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG.
    Breast Cancer Res Treat; 2001 Jan 15; 65(2):125-34. PubMed ID: 11261828
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [The role of raloxifene (Evista) in the treatment and prevention of postmenopausal osteoporosis].
    Korsić M.
    Reumatizam; 2003 Jan 15; 50(2):55-7. PubMed ID: 15098379
    [Abstract] [Full Text] [Related]

  • 20. Medical treatment of vertebral osteoporosis.
    Lippuner K.
    Eur Spine J; 2003 Oct 15; 12 Suppl 2(Suppl 2):S132-41. PubMed ID: 13680313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.